We are live on ! Find out more
RPTX

Repare Therapeutics

Delisted

RPTX was delisted on the 27th of January, 2026.

62 hedge funds and large institutions have $464M invested in Repare Therapeutics in 2022 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 21 increasing their positions, 18 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

174,800% more call options, than puts

Call options by funds: $1.75M | Put options by funds: $1K

17% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 18

0.43% less ownership

Funds ownership: 78.31%77.88% (-0.43%)

7% less funds holding

Funds holding: 6762 (-5)

20% less funds holding in top 10

Funds holding in top 10: 54 (-1)

33% less capital invested

Capital invested by funds: $689M → $464M (-$225M)

38% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 13

Holders
62
Holders Change
-5
Holders Change %
-7.46%
% of All Funds
0.98%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.06%
New
8
Increased
21
Reduced
18
Closed
13
Calls
$1.75M
Puts
$1K
Net Calls
+$1.75M
Net Calls Change
+$1.76M
Name Holding Trade Value Shares
Change
Change in
Stake
BI
1
BVF Inc
California
$83.4M +$14.8M +1,000,015 +21%
O
2
OrbiMed
New York
$47.3M
Fidelity Investments
3
Fidelity Investments
Massachusetts
$41.9M -$1.21M -81,490 -3%
AIM
4
ARK Investment Management
Florida
$40.9M -$1.56M -105,521 -4%
RG
5
Redmile Group
California
$38.9M -$838K -56,500 -2%
DTC
6
Deep Track Capital
Connecticut
$37.9M +$8.36M +564,017 +27%
CA
7
CHI Advisors
New York
$36.8M +$5.47M +368,841 +17%
MAM
8
MPM Asset Management
Massachusetts
$31.9M
T. Rowe Price Associates
9
T. Rowe Price Associates
Maryland
$29.7M -$1.16M -78,477 -4%
MB
10
MPM BioImpact
Massachusetts
$23.4M
AG
11
Artal Group
Luxembourg
$9.97M
AAA
12
Affinity Asset Advisors
New York
$6.68M +$2.92M +197,127 +73%
BlackRock
13
BlackRock
New York
$6.66M +$129K +8,680 +2%
SAM
14
Sectoral Asset Management
Quebec, Canada
$3.39M +$460K +31,000 +15%
Millennium Management
15
Millennium Management
New York
$3.13M -$1.64M -110,672 -33%
UBS AM
16
UBS AM
Illinois
$2.08M -$172K -11,614 -7%
HS
17
HighVista Strategies
Massachusetts
$2.04M +$1.48M +99,878 +230%
Bank of Montreal
18
Bank of Montreal
Ontario, Canada
$2M +$727 +49 +0%
Ensign Peak Advisors
19
Ensign Peak Advisors
Utah
$1.61M +$311K +20,970 +23%
Renaissance Technologies
20
Renaissance Technologies
New York
$1.25M +$20.8K +1,400 +2%
Morgan Stanley
21
Morgan Stanley
New York
$1.18M +$713K +48,091 +138%
State Street
22
State Street
Massachusetts
$1.14M +$266K +17,956 +29%
Vanguard Group
23
Vanguard Group
Pennsylvania
$918K +$5.34K +360 +0.6%
Citadel Advisors
24
Citadel Advisors
Florida
$839K -$84.3K -5,686 -9%
PPA
25
Parametric Portfolio Associates
Washington
$804K +$837K +56,439 New

RPTX Hedge Fund Activity: Q1 2022 in Review

62 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Repare Therapeutics (RPTX) for Q1 2022, worth a combined $464M — down 33% from $689M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of RPTX and 8 opened new positions — a net loss of 5 holders — while 18 trimmed existing stakes and 21 added.

The largest buyer was BVF Inc, adding an estimated $14.8M. The largest seller was Logos Global Management, exiting entirely with an estimated $35.9M sold.

  • 62 institutional investors held Repare Therapeutics (RPTX) as of Q1 2022, down from 67 in Q4 2021.
  • Funds reported $464M of Repare Therapeutics stock for Q1 2022, down 33% quarter-over-quarter.
  • 8 funds opened new Repare Therapeutics positions in Q1 2022 and 13 closed out, a net change of -5 holders.
  • The largest Repare Therapeutics buyer in Q1 2022 was BVF Inc, an estimated $14.8M added.
  • The largest Repare Therapeutics seller in Q1 2022 was Logos Global Management, an estimated $35.9M sold.

Based on aggregated 13F filings for Q1 2022.